Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025Anticipate completing enrollment in ...

Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET. Company Participants. Katie Hogan - Senior Director-Corporate Communications and Investo ...

Almost no other industry goes as far as the phrase "defensive" as the healthcare sector, which encompasses a wide range of ...

With over half the cells in the human body being bacterial rather than human, and over 99% of the genes in the human body ...

Positron emission tomography (PET) scans revealed that he had a small amount of abnormal tau and that it was only in the occipital lobe, a brain region ... and remained constant over the years.

One of the key launch points for the modern biotechnology industry was not in the Bay Area or San Diego or Cambridge, ...

I'm very honored to have assumed responsibilities in the international region that as you all know ... Our full year guidance is, as usual, at constant exchange rates. Based on average January ...

Zoetis, Inc. ZTS delivered fourth-quarter 2024 adjusted earnings (excluding one-time items) of $1.40 per share, which surpassed the Zacks Consensus Estimate of $1.37. In the year-ago quarter, the ...

Sixty (11.9 per cent) of the patients with lymphadenoid goiter manifested a peculiar syndrome of thoracic distress, with puzzling pains in and about the thoracic and shoulder-girdle region.

Ultragenyx Pharmaceutical RARE reported fourth-quarter 2024 loss of $1.39 per share, wider than the Zacks Consensus Estimate of a loss of $1.24. The company had incurred a loss of $1.52 per share in ...

Objectives Tendinopathy is a frequent clinical problem and represents an extraordinary health economic and socioeconomic ...